Cerevel Therapeutics to Present at Upcoming Investor Conferences
08 Novembre 2023 - 12:30PM
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to
unraveling the mysteries of the brain
to treat neuroscience diseases, today announced that
members of the management team will participate in two upcoming
investor conferences during the month of November. President and
chief executive officer Ron Renaud will also participate in
fireside chats at both conferences.
Event: |
Jefferies
London Healthcare Conference |
Date: |
November 14, 2023 |
Time: |
9:00 a.m. GMT fireside chat |
|
|
Event: |
6th Annual Evercore ISI HealthCONx Conference |
Date: |
November 30, 2023 |
Time: |
9:10 a.m. ET fireside chat |
|
Live webcasts of the fireside chats will be
available on the investors section of Cerevel’s website at
investors.cerevel.com. Following the live webcast, an archived
version of the call will be available on the website.
About Cerevel TherapeuticsCerevel Therapeutics
is dedicated to unraveling the mysteries of the brain to treat
neuroscience diseases. The company is tackling diseases by
combining its deep expertise in neurocircuitry with a focus on
targeted receptor subtype selectivity and a differentiated approach
to pharmacology. Cerevel Therapeutics has a diversified pipeline
comprised of five clinical-stage investigational therapies and
several preclinical compounds with the potential to treat a range
of neuroscience diseases, including schizophrenia, Alzheimer’s
disease psychosis, epilepsy, panic disorder, and Parkinson’s
disease. Headquartered in Cambridge, Mass., Cerevel Therapeutics is
advancing its current research and development programs while
exploring new modalities through internal research efforts,
external collaborations, or potential acquisitions. For more
information, visit www.cerevel.com.
Special Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements that are based on management’s beliefs and assumptions
and on information currently available to management. In some
cases, you can identify forward-looking statements by the following
words: “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. Although we believe that we
have a reasonable basis for each forward-looking statement
contained in this press release, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this
press release include, but are not limited to, statements about our
upcoming investor conference participation and the potential
attributes and benefits of our product candidates. We cannot assure
you that the forward-looking statements in this press release will
prove to be accurate. Furthermore, if the forward-looking
statements prove to be inaccurate, the inaccuracy may be material.
Actual performance and results may differ materially from those
projected or suggested in the forward-looking statements due to
various risks and uncertainties, including, among others: clinical
trial results may not be favorable; uncertainties inherent in the
product development process (including with respect to the timing
of results and whether such results will be predictive of future
results); the impact of COVID-19 and the post-COVID landscape on
the timing, progress and results of ongoing or planned clinical
trials; our ability to recruit and enroll suitable patients in our
clinical trials, including the effectiveness of mitigation
measures; whether and when, if at all, our product candidates will
receive approval from the FDA or other regulatory authorities, and
for which, if any, indications; competition from other
biotechnology companies; uncertainties regarding intellectual
property protection; and other risks identified in our SEC filings,
including those under the heading “Risk Factors” in our Quarterly
Report on Form 10-Q filed with the SEC on November 1, 2023 and our
subsequent SEC filings. In light of the significant uncertainties
in these forward-looking statements, you should not regard these
statements as a representation or warranty by us or any other
person that we will achieve our objectives and plans in any
specified time frame, or at all. The forward-looking statements in
this press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required
by applicable law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Media Contact:Anna RobinsonCerevel Therapeutics
anna.robinson@cerevel.com
Investor Contact:Matthew CalistriCerevel
Therapeuticsmatthew.calistri@cerevel.com
Grafico Azioni Cerevel Therapeutics (NASDAQ:CERE)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Cerevel Therapeutics (NASDAQ:CERE)
Storico
Da Mar 2024 a Mar 2025